Susan Groshen

43.0k total citations · 8 hit papers
479 papers, 31.8k citations indexed

About

Susan Groshen is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, Susan Groshen has authored 479 papers receiving a total of 31.8k indexed citations (citations by other indexed papers that have themselves been cited), including 165 papers in Oncology, 145 papers in Surgery and 129 papers in Molecular Biology. Recurrent topics in Susan Groshen's work include Bladder and Urothelial Cancer Treatments (75 papers), Prostate Cancer Treatment and Research (57 papers) and Urinary and Genital Oncology Studies (41 papers). Susan Groshen is often cited by papers focused on Bladder and Urothelial Cancer Treatments (75 papers), Prostate Cancer Treatment and Research (57 papers) and Urinary and Genital Oncology Studies (41 papers). Susan Groshen collaborates with scholars based in United States, Germany and Canada. Susan Groshen's co-authors include Donald G. Skinner, John P. Stein, Gary Lieskovsky, Denice Tsao‐Wei, Richard J. Côté, Heinz‐Josef Lenz, Stuart D. Boyd, Peter W. Nichols, Bernard H. Bochner and Kathleen D. Danenberg and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Susan Groshen

472 papers receiving 30.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients

2001 2.6k citations John P. Stein, Gary Lieskovsky et al. Journal of Clinical Oncology profile →
Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.

2000 704 citations Dennis Salonga, Susan Groshen et al. profile →
Accumulation of Nuclear p53 and Tumor Progression in Bladder Cancer

1994 630 citations David Esrig, Susan Groshen et al. profile →
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

1997 513 citations Susan Groshen, Laila I. Muderspach et al. Journal of Clinical Oncology profile →
ERCC1 and Thymidylate Synthase mRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy

2001 511 citations Susan Groshen, Peter V. Danenberg et al. Journal of Clinical Oncology profile →
Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2

2000 505 citations Denice Tsao‐Wei, Susan Groshen et al. profile →
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines

1999 483 citations Susan Groshen et al. Journal of Clinical Oncology profile →
Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease

2017 393 citations Susan Groshen, Tanya B. Dorff et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Susan Groshen United States	94	12.0k	11.7k	9.1k	6.2k	5.1k	479	31.8k
Richard Sylvester Belgium	88	8.3k 0.7×	24.1k 2.1×	7.0k 0.8×	10.3k 1.7×	4.6k 0.9×	369	36.9k
Arndt Hartmann Germany	76	6.0k 0.5×	6.4k 0.6×	8.7k 1.0×	4.9k 0.8×	4.5k 0.9×	715	21.0k
Nicholas J. Vogelzang United States	89	17.2k 1.4×	10.1k 0.9×	8.4k 0.9×	22.7k 3.6×	6.5k 1.3×	701	41.8k
Atsushi Ochiai Japan	82	11.2k 0.9×	5.2k 0.4×	8.9k 1.0×	7.8k 1.2×	4.2k 0.8×	594	25.1k
Rodolfo Montironi Italy	77	5.9k 0.5×	10.3k 0.9×	9.7k 1.1×	16.3k 2.6×	5.0k 1.0×	877	30.3k
Carolyn C. Compton United States	82	17.1k 1.4×	14.3k 1.2×	5.9k 0.7×	9.4k 1.5×	5.0k 1.0×	319	36.2k
Maria J. Merino United States	98	8.1k 0.7×	5.5k 0.5×	12.3k 1.4×	17.3k 2.8×	7.1k 1.4×	593	37.5k
Holger Moch Switzerland	91	11.4k 1.0×	6.3k 0.5×	18.3k 2.0×	14.7k 2.4×	9.7k 1.9×	604	36.5k
John C. Cheville United States	82	7.5k 0.6×	7.9k 0.7×	12.5k 1.4×	16.6k 2.7×	5.1k 1.0×	511	27.6k
Joaquim Bellmunt United States	77	13.6k 1.1×	15.7k 1.3×	5.9k 0.6×	12.1k 1.9×	3.9k 0.8×	651	30.8k

Countries citing papers authored by Susan Groshen

Since Specialization

Citations

This map shows the geographic impact of Susan Groshen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Groshen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Groshen more than expected).

Fields of papers citing papers by Susan Groshen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan Groshen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Groshen. The network helps show where Susan Groshen may publish in the future.

Co-authorship network of co-authors of Susan Groshen

This figure shows the co-authorship network connecting the top 25 collaborators of Susan Groshen. A scholar is included among the top collaborators of Susan Groshen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Groshen. Susan Groshen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hogarty, Michael D., David S. Ziegler, Andrea Franson, et al.. (2024). Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial. British Journal of Cancer. 130(5). 788–797. 10 indexed citations

Frankel, Paul, et al.. (2023). Ethics and Clinical Research: Improving Transparency and Informed Consent in Phase I Oncology Trials. Journal of Clinical Oncology. 41(12). 2155–2158. 3 indexed citations

Thomas, Jacob, Anthony B. El-Khoueiry, Barry J. Maurer, et al.. (2021). A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors. Cancer Chemotherapy and Pharmacology. 87(4). 525–532. 14 indexed citations

Tuscano, Joseph M., Emanual Maverakis, Susan Groshen, et al.. (2019). A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma. Clinical Cancer Research. 25(23). 7004–7013. 34 indexed citations

Mohrbacher, Ann, Allen S. Yang, Susan Groshen, et al.. (2017). Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial. Clinical Cancer Research. 23(16). 4550–4555. 28 indexed citations

Ha, Dat P., Genyuan Zhu, Agnieszka Kobielak, et al.. (2017). GRP78 haploinsufficiency suppresses acinar-to-ductal metaplasia, signaling, and mutant Kras -driven pancreatic tumorigenesis in mice. Proceedings of the National Academy of Sciences. 114(20). E4020–E4029. 39 indexed citations

Stany, Michael P., Pamela Stone, Janine F. Felix, et al.. (2015). Lymph Node Micrometastases in Early-Stage Cervical Cancer are Not Predictive of Survival. International Journal of Gynecological Pathology. 34(4). 379–384. 14 indexed citations

Little, Gillian H., Sanjeev K. Baniwal, Helty Adisetiyo, et al.. (2014). Differential Effects of RUNX2 on the Androgen Receptor in Prostate Cancer: Synergistic Stimulation of a Gene Set Exemplified by SNAI2 and Subsequent Invasiveness. Cancer Research. 74(10). 2857–2868. 31 indexed citations

Liu, Stephen V., Denice Tsao‐Wei, Shigang Xiong, et al.. (2014). Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer. Clinical Cancer Research. 20(24). 6277–6283. 37 indexed citations

10.

Ara, Tasnim, Rie Nakata, Michael A. Sheard, et al.. (2013). Critical Role of STAT3 in IL-6–Mediated Drug Resistance in Human Neuroblastoma. Cancer Research. 73(13). 3852–3864. 105 indexed citations

11.

Dong, Dezheng, Christopher J. Stapleton, Biquan Luo, et al.. (2011). A Critical Role for GRP78/BiP in the Tumor Microenvironment for Neovascularization during Tumor Growth and Metastasis. Cancer Research. 71(8). 2848–2857. 127 indexed citations

12.

Stadler, Walter M., Seth P. Lerner, Susan Groshen, et al.. (2011). Phase III Study of Molecularly Targeted Adjuvant Therapy in Locally Advanced Urothelial Cancer of the Bladder Based on p53 Status. Journal of Clinical Oncology. 29(25). 3443–3449. 165 indexed citations

13.

Mitra, Anirban P., Vincenzo Pagliarulo, Dongyun Yang, et al.. (2009). Generation of a Concise Gene Panel for Outcome Prediction in Urinary Bladder Cancer. Journal of Clinical Oncology. 27(24). 3929–3937. 84 indexed citations

14.

Ara, Tasnim, Liping Song, Hiroyuki Shimada, et al.. (2008). Interleukin-6 in the Bone Marrow Microenvironment Promotes the Growth and Survival of Neuroblastoma Cells. Cancer Research. 69(1). 329–337. 145 indexed citations

15.

Saha, Baisakhi, Denice Tsao‐Wei, Wesley Y. Naritoku, et al.. (2007). Overexpression of E‐cadherin and β‐Catenin proteins in metastatic prostate cancer cells in bone. The Prostate. 68(1). 78–84. 49 indexed citations

16.

Peng, Hongjun, Yasuyoshi Sohara, Rex Moats, et al.. (2007). The Activity of Zoledronic Acid on Neuroblastoma Bone Metastasis Involves Inhibition of Osteoclasts and Tumor Cell Survival and Proliferation. Cancer Research. 67(19). 9346–9355. 41 indexed citations

17.

Lee, Eunjung, Peter W. Nichols, Darcy Spicer, et al.. (2006). GRP78 as a Novel Predictor of Responsiveness to Chemotherapy in Breast Cancer. Cancer Research. 66(16). 7849–7853. 240 indexed citations

18.

Pagliarulo, Vincenzo, Debra Hawes, F. Brands, et al.. (2006). Detection of Occult Lymph Node Metastases in Locally Advanced Node-Negative Prostate Cancer. Journal of Clinical Oncology. 24(18). 2735–2742. 82 indexed citations

19.

Formenti, Silvia C., Darcy Spicer, Kristin A. Skinner, et al.. (2002). Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer. International Journal of Radiation Oncology*Biology*Physics. 52(2). 397–405. 32 indexed citations

20.

Keung, Yi‐Kong, et al.. (1994). Comparative study of infections complications of different types of chronic central venous access devices. Cancer. 73(11). 2832–2837. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact